Molecular Profile Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
PBRM1 loss	melanoma	sensitive	unspecified CTLA4 antibody + unspecified PD-1 antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958).	29301958
PBRM1 loss	lung cancer	sensitive	PRT1419 + Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625).	38371625
PBRM1 loss	lung cancer	sensitive	PRT2527	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRT2527 inhibited tumor growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625).	38371625
PBRM1 loss	lung cancer	sensitive	PRT2527 + Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PRT2527 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625).	38371625

Profile Name	PBRM1 loss
Gene Variant Detail	PBRM1 loss (loss of function)
Relevant Treatment Approaches	EZH2 inhibitor